Skip to Content

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Published Date: April 16, 2025

This expert-led session offers oncology professionals a comprehensive overview of MZL subtypes, traditional treatment pathways, and the promising role of targeted oral therapies—specifically BTK inhibitors such as zanubrutinib.

Topics covered include:

  • The unique characteristics and prognosis of the three MZL subtypes: MALT lymphoma, nodal MZL, and splenic MZL
  • The evolving role of targeted therapies in treating relapsed or refractory MZL
  • Clinical data and outcomes from the MAGNOLIA study on zanubrutinib
  • Detailed information on dosing strategies, safety profile, and patient management considerations
  • Guidance on managing drug interactions, side effects, and special patient populations

 

View Prescribing Information

Sponsored by